
In final draft guidance, the National Institute for Health and Clinical Excellence (NICE) here has recommended an intravitreal implant that delivers 0.7 mg of dexamethasone via an applicator (Ozurdex, Allergan) for the treatment of macular edema (ME) due to central retinal vein occlusion and also for branch retinal vein occlusionin cases in which laser photocoagulation is neither beneficial nor appropriate.